Multicenter, international, phase 3, double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety, and tolerability of tafamidis in subjects diagnosed with transthyretin cardiomyopathy (TTR-CM)

The study will enroll up to 400 patients with both transthyretin familial amyloid cardiomyopathy (TTR-FAC) and non-hereditary (wild-type/senile systemic amyloidosis) cardiomyopathy.

Primary objective: Determine the efficacy, safety and tolerability of tafamidis meglumine in comparison to placebo and given once daily for 30 months in subjects diagnosed with either TTR variant or wild-type transthyretin cardiomyopathy

For more information, please contact Dr Jennifer Schumacher at Pfizer:
  jennifer.schumacher@pfizer.com                 Phone: (612) 388 8763
ENROLLING SOON

Multicenter, international, phase 3, double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety, and tolerability of tafamidis in subjects diagnosed with transthyretin cardiomyopathy (TTR-CM)

The study will enroll up to 400 patients with both transthyretin familial amyloid cardiomyopathy (TTR-FAC) and non-hereditary (wild-type/senile systemic amyloidosis) cardiomyopathy.

Primary objective: Determine the efficacy, safety and tolerability of tafamidis meglumine in comparison to placebo and given once daily for 30 months in subjects diagnosed with either TTR variant or wild-type transthyretin cardiomyopathy

For more information, please contact Dr Jennifer Schumacher at Pfizer: jennifer.schumacher@pfizer.com Phone: (612) 388 8763
ENROLLING SOON

Multicenter, international, phase 3, double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety, and tolerability of tafamidis in subjects diagnosed with transthyretin cardiomyopathy (TTR-CM)

The study will enroll up to 400 patients with both transthyretin familial amyloid cardiomyopathy (TTR-FAC) and non-hereditary (wild-type/senile systemic amyloidosis) cardiomyopathy.

Primary objective: **Determine the efficacy, safety and tolerability of tafamidis meglumine in comparison to placebo and given once daily for 30 months in subjects diagnosed with either TTR variant or wild-type transthyretin cardiomyopathy**

For more information, please contact Dr Jennifer Schumacher at Pfizer: jennifer.schumacher@pfizer.com  Phone: (612) 388 8763